A Review of Endocrine Therapy in Early-stage Breast Cancer: The Journey From Crudeness to Precision. (1st May 2023)

• Record Type: Journal Article
• Authors: Elayoubi, Jailan; Chi, Jie; Mahmoud, Amr A.; Alloghbi, Abdurahman; Assad, Hadeel; Shekhar, Malathy; Simon, Michael S.
• Is Part Of: American journal of clinical oncology. Volume 46:Number 5(2023)
• Page Start: 225
• Page End: 230
• Publication Date: 2023-05-01
• Subjects: endocrine therapy -- adjuvant ET -- neoadjuvant ET -- window of opportunity trials -- molecular profiling -- hormone receptor -- early-stage breast cancer; Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0000000000000993
• Languages: English
• ISSNs: 0277-3732

Abstract

Abstract : Endocrine therapy (ET) is the standard of care for hormone receptor-positive early-stage breast cancer in the adjuvant setting. However, response to ET can vary across patient subgroups. Historically, hormone receptor expression and clinical stage are the main predictors of the benefit of ET. A "window of opportunity" trials has raised significant interest in recent years as a means of assessing the sensitivity of a patient's cancer to short-term neoadjuvant ET, which provides important prognostic information, and helps in decision-making regarding treatment options in a time-efficient and cost-efficient manner. In the era of genomics, molecular profiling has led to the discovery and evaluation of the prognostic and predictive abilities of new molecular profiles. To realize the goal of personalized medicine, we are in urgent need to explore reliable biomarkers or genomic signatures to accurately predict the clinical response and long-term outcomes associated with ET. Validation of these biomarkers as reliable surrogate endpoints can also lead to a revolution in the clinical trial designs, and potentially avoid the need for repeated tissue biopsies in the surveillance of disease response. The clinical potential of tumor genomic profiling marks the beginning of a new era of precision medicine in breast cancer treatment.